Spero Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRO research report →
About the company
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients.
- CEO
- Esther Rajavelu
- IPO
- 2017
- Employees
- 32
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $127.38M
- P/E
- 8.16
- P/S
- 2.33
- P/B
- 2.38
- EV/EBITDA
- 4.95
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 24.66%
- Net Margin
- 27.82%
- ROE
- 35.58%
- ROIC
- 23.93%
- Revenue
- $59.62M · 24.27%
- Net Income
- $8.57M · 112.50%
- EPS
- $0.15 · 111.81%
- Op Income
- $-24,000
- FCF YoY
- 46.15%
- 52W High
- $3.22
- 52W Low
- $1.80
- 50D MA
- $2.58
- 200D MA
- $2.41
- Beta
- 1.49
- Avg Volume
- 1.00M
Get TickerSpark's AI analysis on SPRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Deshpande Milind | other | 10,000 |
| Jun 23, 26 | Deshpande Milind | other | 20,000 |
| Jun 23, 26 | Tregoning Kathleen | other | 10,000 |
| Jun 23, 26 | Tregoning Kathleen | other | 20,000 |
| Jun 23, 26 | Smith Cynthia | other | 10,000 |
| Jun 23, 26 | Smith Cynthia | other | 20,000 |
| Jun 23, 26 | VINK PATRICK V.J.J. | other | 10,000 |
| Jun 23, 26 | VINK PATRICK V.J.J. | other | 20,000 |
| Jun 23, 26 | THOMAS FRANK E | other | 10,000 |
| Jun 23, 26 | THOMAS FRANK E | other | 20,000 |
Our SPRO coverage
Recent articles, reports, and earnings notes.
Want a deeper read on SPRO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.